一个候选DNA疫苗编码原生SARS-CoV-2尖端蛋白诱导抗子域1抗体
Anders Frische1,2, Vithiagaran Gunalan1, Karen Angeliki Krogfelt1,2
1Department of Virus & Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.
Vaccines
|September 28, 2023
概括
设计有效的疫苗需要识别抗体点. 这项研究发现,在尖端蛋白上准特定的非RBD表位物可以增强针对SARS-CoV-2关注变体 (VOCs) 的交叉中和.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
背景情况:
- 广泛的保护性疫苗需要针对保存的病毒表位的抗体.
- 了解疫苗诱导的多克隆抗体反应对于设计有效疫苗至关重要.
- 针对SARS-CoV-2的疫苗诱导抗体的B细胞表位仍然定义不佳.
研究的目的:
- 识别与对抗SARS-CoV-2变种的中和宽度相关的独特抗体标.
- 调查抗体概况与中和效率之间的相关性.
- 为合理设计广泛保护性SARS-CoV-2疫苗提供信息.
主要方法:
- 结合中和抗体功能测试与B细胞表皮图映射.
- 在接种了SARS-CoV-2疫苗的子中分析了多克隆抗体概况.
- 评估了针对不同SARS-CoV-2令人担忧的变种 (VOC) 的中和效率.
主要成果:
- 不同的多克隆抗体配置与对VOCs的不同中和效率相关.
- 具有中等和高交叉中和度的子准了较少的尖端蛋白抗原位.
- 在受体结合域 (RBD) 外的子域1 (SD1) 中的一个特定表位被确定为关键目标.
结论:
- 针对特定的非RBD表位体,如SD1,可以增强功能性抗体反应,以获得广泛的保护.
- 开发的方法可以识别用于未来病毒疫苗设计的交叉中和表位.
- 这些发现支持一项专注于针对性抗体反应和非RBD表位的策略,用于SARS-CoV-2疫苗开发.
相关概念视频
Cross-reactivity
31.2K
Overview
31.2K
Antibody Structure
60.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.3K


